Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CVS Caremark
CVS Caremark Praises FTC Report Supporting Pro-Consumer Approach to Biogeneric Competition
June 28th, 2009
CVS Caremark (NYSE:CVS) today applauded a Federal Trade Commission (FTC) report issued this week for its pro-consumer leadership in the debate about how to create a legislative pathway for the approval of biogenerics that reasonably balances innovation with competition. Dave Golding, R.Ph., Executive Vice President for Specialty Pharmacy services at CVS Caremark, participated in an FTC Roundtable event last fall on the issue. In addition, the company has provided data to the Commission to assist in its research. "CVS Caremark serves hundreds of thousands of patients who rely on specialty and other biologic medicines to provide life-saving treatments...
Source: Pharma Investments, Ventures & Law Weekly (2009-06-28)
|
